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ABSTRACT
Objectives Some studies have reported a possible
association between exposure to tumour necrosis factor
(TNF) inhibitors and an increased risk of melanoma. The
aim of this study was to investigate the incidence of
invasive cutaneous melanomas in patients with
rheumatoid arthritis (RA) treated with TNF inhibitors
(TNFi), other biologic disease modifying drugs and non-
biologic therapy.
Methods Eleven biologic registers from nine European
countries participated in this collaborative project.
According to predeﬁned exposure deﬁnitions, cohorts of
patients with RA were selected. Using the country-
speciﬁc general population of each register as reference,
age, sex and calendar year standardised incidence ratios
(SIRs) of invasive histology-conﬁrmed cutaneous
melanoma were calculated within each register. Pooled
SIR and incidence rate ratios (IRRs) comparing biologic
cohorts to biologic-naïve were calculated across countries
by taking the size of the register into account.
Results Overall 130 315 RA patients with a mean age
of 58 years contributing 579 983 person-years were
available for the analysis and 287 developed a ﬁrst
melanoma. Pooled SIRs for biologic-naïve, TNFi and
rituximab-exposed patients were 1.1 (95% CI 0.9 to
1.4), 1.2 (0.99 to 1.6) and 1.3 (0.6 to 2.6), respectively.
Incidence rates in tocilizumab and abatacept-exposed
patients were also not signiﬁcantly increased. IRR versus
biologic-naïve patients were: TNFi 1.1 (95% CI 0.8 to
1.6); rituximab 1.2 (0.5 to 2.9).
Conclusions This large European collaborative project
did not conﬁrm an overall increased risk of melanoma
following exposure to TNFi.
INTRODUCTION
Invasive cutaneous malignant melanoma (hereafter
referred to as melanoma) is the sixth most fre-
quently diagnosed cancer in Europe with an age
standardised incidence rate of 11.1 per 100 000 in
2012.1 The incidence of melanoma varies across
European countries, with rates highest in northern
Europe.2 Melanoma is immunogenic and patients
with impaired immunity, for example, due to solid
organ transplantation or AIDS, are at increased risk
of melanoma.3–5 Whether, and to what degree,
patients with rheumatoid arthritis (RA) are also at
increased risk is less clear. Conﬂicting results were
reported in patients with biologic-naïve RA.6–10
With the introduction of biologic therapies and in
particular tumour necrosis factor inhibitors (TNFi)
to the treatment of RA and other diseases, concerns
were raised that these therapies may increase the
risk of malignancy and in particular melanoma.5 11 12
TNF may play a protective role in the growth or
recurrence risk of melanoma13 14 and high dose,
locally administered TNF has been shown to have a
powerful antineoplastic effect against melanoma.15
No overall increased risk of solid tumours has been
observed in a large Swedish population-based study,
a later meta-analyses of RCTs, and in other observa-
tional cohort studies.11 12 16–19 Conversely, both
meta-analysis of randomised controlled trials and
observational cohort studies have raised concerns
regarding an increased risk of melanoma and non-
melanoma skin cancer in patients who had RA
treated with TNFi,5 11 12 20 21 supporting the
hypothesis of a causal pathway from TNF inhibition
to developing melanoma.
Because of these concerns, representatives from
11 European biologic registers undertook a collab-
orative project to investigate the risk of developing
invasive melanoma in patients who had RA treated
with conventional synthetic or biologic disease
modifying antirheumatic drugs (DMARDs) under
the auspices of the European League Against
Rheumatism (EULAR) Registers and Observational
Drug Studies (RODS) Study Group. The aim of this
study was to conduct a collaborative project across
several European countries to compare rates of inva-
sive melanoma in different treatment groups of
patients with RA to those in the general population.
PATIENTS AND METHODS
Study design
The study population was assembled by a working
group of representatives from European biologic
registers within the EULAR RODS Study Group.
The working group met three times in 2013 and
2014, discussed objectives of the project, data
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ascertainment methods, proposals for a coordinated analysis,
agreed-upon the statistical analysis plan and ﬁnally discussed
ﬁrst results and possible limitations of the ﬁndings. The follow-
ing registers participated in this project: French biologic register
‘autoimmunity and rituximab’ (AIR),22 Swedish biologics regis-
ter (ARTIS),23 Czech biologics register (ATTRA), British Society
for Rheumatology Biologics Register for Rheumatoid Arthritis
(BSRBR-RA),24 Danish Rheumatologic database (DANBIO),25
Italian biologic register (GISEA), French biologic register
‘Orencia and RA’,22 German biologics register ‘Rheumatoid
arthritis observation of biologic therapy’ (RABBIT),17 French
REGistry—RoAcTEmra,22 Portuguese RA register (Reuma.pt)
and Swiss Clinical Quality Management Database. Registries
were required to have at least one melanoma reported among
patients with RA in order to participate. Each registry study was
given approval by their local Data Protection Agency/ethics
committee according to local regulations.
Patients
Patients were required to have RA and be prospectively
followed-up in one participating European biologic register.
Patients with a history of invasive melanoma prior to registra-
tion were excluded to prevent the inclusion of recurrent lesions.
Patients with prior melanoma in situ were permitted to enter
the analysis due to difﬁculties in identifying such patients accur-
ately and misclassiﬁcation between melanoma in situ and benign
lesions. Cohorts of biologic-naïve patients and patients treated
with TNFi, rituximab (RTX), tocilizumab (TOC) and abatacept
(ABT) were assembled. Based on previous ﬁndings5 which did
not observe an association between melanoma occurrence and
exposure time to TNFi we did not differentiate between cohorts
with shorter or longer mean length of follow-up/shorter or
longer exposure times to TNFi or other biologic and non-
biologic DMARDs.
One exposure deﬁnition was used for the biologic-naïve
cohorts: patients had to be biologic-naïve at the time of ﬁrst
registration and at follow-up. Exposure time started at ﬁrst regis-
tration and was censored either at the date of invasive melan-
oma, death, end of follow-up or the date of receiving a ﬁrst
biologic drug, whichever came ﬁrst.
Three exposure deﬁnitions were applied in the anti-TNF
cohorts: prior exposure to biologic drugs (other than anakinra)
was not permitted in any of the corresponding anti-TNF
cohorts. An ‘ever-exposed’ approach was used in the primary
analysis. Patients were at risk and contributed follow-up time to
the anti-TNF cohort from the ﬁrst dose of an anti-TNF drug
after registration until invasive melanoma, death or end of
follow-up (no later than 30 April 2014). In a second ‘most
recent drug’ approach, a switch to a non-anti-TNF drug also led
to a censoring of the subsequent observation time. In a third
on-drug approach the observation time was censored 3 months
after treatment termination, invasive melanoma, death or end of
follow-up (no later than 30 April 2014), whichever came ﬁrst.
In the case of the RTX, TOC and ABT cohorts, the same
three exposure deﬁnitions were applied. In the third approach
patients were considered on RTX treatment 9 months after the
last dose. Prior exposure to TNFi was allowed for non-anti-TNF
biologics, reﬂecting real-world practice during the period of
data collection.
In registries where a drug cohort had fewer than 1000
person-years (pyrs) of follow-up accumulated this subcohort
was excluded from the analysis, since these subcohorts very
likely contribute only to the denominator (pyrs) but not to the
numerator (number of events) of the incidence rates. In the case
of the BSRBR-RA TOC cohort, this exclusion led, however, also
to the exclusion of one melanoma case. Nevertheless, the exclu-
sion had no inﬂuence on the signiﬁcance of the TOC results.
Outcome
The outcome was ﬁrst invasive melanoma (cutaneous or meta-
static). Three registries received reports of melanoma through
linkage of all participants to their national cancer registry:
DANBIO (Denmark), ARTIS (Sweden) and BSRBR-RA (UK).
The remaining registries (as well as the UK) received reports of
melanoma from the patient’s rheumatologist. These melanomas
were required to be conﬁrmed by histology report.
Statistical analyses
The incidence of melanoma in the general populations of the
participating countries varied considerably (table 1). To deal
with these differences and the increasing melanoma incidences
over time (see ref. 2), melanoma incidence rates were ﬁrst com-
pared with age-matched and sex-matched incidences in the
general population of the corresponding country and calendar
year. For that reason the observation time of each cohort within
one calendar year was stratiﬁed by sex and 5 years age bands
and then the expected number of melanomas within that cohort
in the speciﬁc calendar year was calculated based on the
age-stratiﬁed and sex-stratiﬁed population data of the corre-
sponding register in the corresponding calendar year.
Standardised incidence ratios (SIRs) were then calculated by div-
iding the sum of observed melanoma by the sum of expected
melanomas.
Therefore, the calculation of SIRs took account of temporal
changes in the melanoma incidence in the general populations
over the course of data collection for this study (see ref. 2).
Poisson regression models were used to summarise the register-
speciﬁc SIRs to overall SIR estimates as weighted sums of indi-
vidual SIRs such that the weights were higher for cohorts with
higher numbers of events.
SIRs of melanoma in biologic-exposed patients were com-
pared with those in biologic-naïve patients within countries by
calculating incidence rate ratios (IRRs). Overall IRRs were calcu-
lated, again weighting according to the number of events in the
registers. To explore whether or not the variation in the SIRs
can be completely explained by random variation due to low
numbers of events, the Marshall and DerSimonian Laird
methods to estimate the systematic heterogeneity in the SIRs
Table 1 Means of age-standardised incidence rates of melanoma
(years 2003–2012) using the European standard population aged
40–84 as reference
Annual incidence of melanoma in the general
population (per 100 000)
Total Males Females
Sweden 47.1 51.3 42.9
Denmark 52.2 53.3 51.2
UK 30.6 32.1 29.1
Germany 31.6 35.1 28.0
Czech Republic 34.0 40.0 28.0
France 22.9 23.3 22.5
Switzerland 48.6 54.5 42.7
Portugal 11.6 11.0 12.1
Italy 27.9 33.0 22.8
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were applied.26 Generally speaking heterogeneity is measured
by the observed variability in the SIRs minus the expected vari-
ability due to low event numbers. In the case of zero (no) het-
erogeneity the result of this difference might be negative, it will
then be reported to be zero. Since the two methods agreed only
one result is reported.26
Furthermore, in sensitivity analyses SIRs and IRRs were also
calculated for females and males separately as well as for
patients aged 55–74, because in a previous analysis from ARTIS
the risk of melanoma in patients exposed to TNFi was noted to
be higher in men and those aged 55–74.5 To explore a possible
under-reporting of rheumatologists, SIRs and IRRs observed in
registers with record linkage to cancer registries were compared
with the corresponding SIR or IRR estimates in the remaining
registers by means of Poisson regression. To compare incidence
rates in the general population, country and calendar year-
speciﬁc incidence rates of melanoma in the general populations
were standardised by using the European standard population
(WHO 1990) aged 40–84 as reference.
RESULTS
Overall 130 315 patients from 11 registers contributing
579 983 pyrs were included. The mean age at the time of ﬁrst
registration ranged between 50 (ATTRA TNFi cohort) and 62
Table 2 Baseline characteristics of biologic-naïve, TNFi rituximab, tocilizumab or abatacept ever-exposed RA patients
Biologic-naïve TNFi Rituximab Tocilizumab Abatacept
Patients (n) 68 411 48 304 9431 2606 1563
Follow-up time (pyrs) 300 012 242 814 28 705 4053 4399
Female (%) (range) 72.1 (71–79) 75 (74.2–87) 78.4 (76.1–80.5) 78.8 (77–80.2) 78.4 (77–79.2)
Mean age (range) 61.1 (57–61.8) 55.0 (50.3–56.5) 58 (57.5–58.6) 56.5 (56–56.8) 57.4 (56–58.2)
Mean of median disease duration (range) 5.7 (4–13) 8.5 (6.2–12) 12.8 (8.6–17) 10.3 (6–13.5) 13.3 (8–16)
Mean DAS28 (range) 4.0 (3.6–5.1) 5.3 (3.8–6.6) 5.4 (4.3–5.7) 5.2 (5.1–5.3) 5.3 (5.3–5.4)
Mean HAQ (range) 1.0 (0.8–1.5) 1.4 (0.8–2) 1.5 (1.2–1.6) 1.4 1.5
DAS28, disease activity score based on 28 joint counts; HAQ, Health Assessment Questionnaire; Pyrs, person-years; TNFi, tumour necrosis factor inhibitors.
Figure 1 Standardised incidence ratios (SIRs) of melanoma in: (A) biologic-naïve, (B) tumour necrosis factor inhibitors (TNFi) ever exposed,
(C) rituximab ever exposed, (D) tocilizumab ever exposed and (E) abatacept ever exposed patients with RA. obs, Observed melanoma.
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(ARTIS) (table 2) years. Similar large variations were observed
for the portion of female patients ranging between 65% (GISEA
TNF cohort) and 87% (Reuma.pt TNFi cohort) and the median
disease duration of RA, which was lowest in the biologic-naïve
DANBIO cohort (3.9 years) and highest in RTX-treated patients
in AIR (17 years).
Comparisons to the general populations by means of SIRs
In total 287 patients developed a ﬁrst melanoma. Overall 160
melanomas were reported in biologic-naïve patients with RA
from ﬁve countries (ﬁgure 1A). Using country and calendar
year-speciﬁc melanoma rates in the general populations of the
corresponding biologic registers as reference only minor varia-
tions in the SIRs across registries and a minor non-signiﬁcant
increase in the overall SIR: 1.1 (95% CI 0.9 to 1.4) were
observed. A total of 106 patients developed a ﬁrst melanoma
in patients ever exposed to TNFi. A larger variation was
observed in the SIR in TNFi-exposed patients between registries
(ﬁgure 1B). Furthermore, the overall SIR observed in registers
with data linkage to cancer registries (Sweden, Denmark, UK)
was numerically higher 1.3 (0.85 to 2.1) but did not achieve
statistical signiﬁcance. In general, the observed variation was
attributable to random variation because of low numbers of
cases of melanoma within individual registers. The portion of
the variation attributable to systematic heterogeneity was esti-
mated to be 0%. After combining the country-speciﬁc results to
an overall SIR a small increase in the melanoma incidence of
TNFi ever exposed patients was observed (SIR 1.2 (0.99 to
1.6), p=0.062). The most recent drug use approach resulted in
a similar ﬁnding. Ninety-three melanomas in 220 259 pyrs of
TNF-exposed patients corresponded to an SIR of 1.2 (0.9 to
1.6). Using the on-drug approach 77 melanomas were observed
in 188 051 pyrs of TNF-exposed patients (SIR 1.2 (0.8 to 1.8)).
No signiﬁcantly increased melanoma incidence and no hetero-
geneity between the register-speciﬁc results were observed in
patients ever (13 melanoma in 28 707 pyrs, SIR 1.3 (0.6 to
2.6)) or most recently (11 melanoma in 23 248 pyrs, SIR 1.4
(0.6 to 3.2)) exposed to RTX (ﬁgure 1C). Limited data were
available for TOC and ABT-treated patients. For that reason
very wide 95% CIs of the SIR estimates were calculated for
TOC ever (four melanoma in 4053 pyrs, SIR 3.4 (0.0 to 1930),
p=0.25) or ABT ever (two melanoma in 4399 pyrs, SIR 1.6
(0 to 12 704), p=0.63) exposed patients.
Comparisons between biologic-naïve patients and TNFi,
RTX, TOC or ABT-exposed patients
The comparison of the SIRs of biologic-exposed patients with
the SIRs of biologic-naïve patients resulted in slightly but non-
signiﬁcantly increased IRRs for TNFi and RTX-exposed patients
(ﬁgure 2A, B). The IRR global of TNFi ever exposed patients
was 1.14 (0.8 to 1.6). In registers with data linkage to cancer
registries (Sweden, Denmark, UK) the IRR of TNFi ever
exposed patients was slightly higher (IRR: 1.2 (0.8 to 1.7)) but
did not differ signiﬁcantly from those observed in registers
which relied solely on physician reporting of melanomas
(IRR=1.1, p=0.28). SIRs of TOC and ABT-treated patients also
did not differ signiﬁcantly from the SIRs in biologic-naïve
patients.
Sensitivity analyses
Sensitivity analyses performed separately in males and females
were similar to previous ﬁndings in the Swedish register with
lower IRRs of TNFi ever exposed females (IRR 0.9 (0.4 to 1.9)
vs IRR males: 1.6 (0.6 to 4.4)). However, none of these IRRs
differed signiﬁcantly from 1. The SIR of Swedish TNFi patients
aged 50–74 at time of melanoma diagnosis was numerically
higher than the corresponding SIR of Swedish biologic-naïve
patients (ﬁgure 3). Across the three registers with sufﬁcient data
in these subcohorts there was no signiﬁcant difference between
both treatment exposure groups (IRR=1.39 (0.6 to 3.3)).
DISCUSSION
In all treatment groups the incidence of invasive melanoma was
slightly higher in RA than in the corresponding general popula-
tions of the participating countries. Nevertheless, even with this
large European collaborative project of 11 registers from nine
countries the previous signal of an increased risk of melanoma
following TNFi reported by ARTIS5 and DANBIO12 was not
Figure 2 Melanoma incidence rate ratios (IRRs) of (A) tumour necrosis factor inhibitors (TNFi) ever exposed and (B) rituximab ever exposed
patients compared with biologic-naïve patients.
Figure 3 Subgroup analysis: standardised incidence ratios (SIRs) of
melanomas in patients aged 50–74 years at the time of melanoma
diagnosis. TNF, tumour necrosis factor.
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replicated across the other registries in this study. We did not
detect a signiﬁcant overall increase in the age and sex standardised
incidence ratios. No signiﬁcant differences in the melanoma
incidence were observed between biologic-naïve patients and
patients exposed to TNFi, RTX, ABTor TOC. Sensitivity analyses
of subcohorts of TNFi-exposed patients conﬁrmed these
ﬁndings, whereas limited sample sizes require a cautious inter-
pretation of the ﬁndings for patients treated with ABTand TOC.
We were furthermore not able to conﬁrm a previous ﬁnding
of an increased melanoma risk in RA males or RA patients aged
50–74 who were treated with TNFi.5
It is a notable achievement that we were able to bring
together investigators from multiple national biologics registers
in order to undertake this collaborative analysis. Despite the
power of individual national registers, there remain safety con-
cerns of clinical importance that individual registers are unable
to address with conﬁdence. Here, we were able to collate over
half a million person-years of monitoring across Europe. Similar
to others we assumed that treatment decisions were made inde-
pendently of skin type and patients’ behaviour to deal with
exposure to ultra violet radiation. The application of rather
strict case validation methods and the consideration of different
exposure models contributed to the strengths of this study.
Nevertheless, the validity of our ﬁndings depends on the valid-
ity of the data of each subcohort. The impact of biases or
residual confounding in individual datasets on the summary
results cannot be estimated or controlled for. We presumed that
dropouts and especially measures to detect melanoma early in
an in situ stage had no different impact on the results in
biologic-naïve or bDMARD-treated patients. Furthermore, the
SIR for melanoma risk in TNFi-treated patients was numerically
higher, although not statistically different, when limited to
countries with linkage to cancer registries (Denmark, Sweden,
UK). This raises the possibility that ascertainment of melanoma
cases was incomplete in other registries. Considering these lim-
itations we cannot completely rule out an increased melanoma
risk in patients with RA treated with TNFi. Nonetheless, the
ﬁndings of the different registers were rather consistent. We
detected no systematic heterogeneity between the country-
speciﬁc SIRs. For these reasons we conclude that this large
European collaborative project did not conﬁrm an overall
increased risk of melanoma following exposure to TNFi.
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